Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy

NCT07241104 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07241104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07241104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2025
Completion date
November 22, 2027
Enrollment
23 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dilated cardiomyopathy